PRA understands how cerebrospinal fluid (CSF) sampling benefits our clients’ early phase trials. We regularly conduct CSF sampling to collect key PK and PD information necessary for clients’ go/no go decisions and to determine appropriate dosing ranges in Phase II studies.
Explore related content and topics
White Paper
Favorable Regulatory Procedures In The Netherlands Phase I-IIa
The EU Clinical Trials Directive (CTD) has been fully implemented in The Netherlands. Prior to beginning a clinical trial, an identical Clinical…
View Resource
Poster
Human Abuse Liability Studies: Not Your Traditional Phase I Study
Abuse potential refers to the likelihood for a drug to be used in nonmedical situations for its positive psychoactive effects. PRA Health Sciences’…
View Resource
Poster
Retrospective Analysis of the Effects of Protocol Design on Completion Rates in Phase 1 Studies in Subjects with Stable Schizophrenia
Subject attrition from randomized Schizophrenia trials is a significant problem and has been found in meta-analysis to be as high as 76% (Robinowitz…
View Resource
View all related content and resources for Clinical Pharmacology
Explore Insights